Cuatrecasas advise in Deepull Series C investment round for 50 million euros

Cuatrecasas has advised Deepull Diagnostics in its Series C investment round for 50 million euros.

Deepull, a developer of culture-free medical diagnostic solutions, will use the funds to complete clinical validations and advance the regulatory approval process for the UllCORE system, which last December was highlighted as a Breakthrough Device by the U.S. Food and Drug Administration. It is a fully automated, hands-free system that uses cutting-edge molecular techniques to extract and detect microbial DNA directly from blood. The test covers 95% of the pathogens that cause sepsis, including bacteria and fungi, as well as antibiotic resistance genes, providing results in approximately one hour.

The achievement of this new round is a crucial milestone for Deepull, which is thus moving towards the completion of clinical studies of its diagnostic system, with the goal of delivering a transformative diagnostic solution to healthcare professionals and patients around the world.

“It is a privilege to have accompanied Deepull and its partners from the beginning of this exciting project to this important milestone: the successful completion of the Series C round. This achievement, which allows the company to take on new challenges and boost its growth, is another example of the dynamism of the life sciences industry in our region,” said Elena Cuatrecasas, who led the legal advice on the transaction, in close collaboration with lawyers Amador Rodríguez and Georgina Bofill.